Literature DB >> 24764725

A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients.

Inanç Değer Fidancı1, Bülent Zülfikar2, Kaan Kavaklı3, M Cem Ar4, Yurdanur Kılınç5, Zafer Başlar6, Server Hande Cağlayan1.   

Abstract

OBJECTIVE: A severe complication in the replacement therapy of hemophilia A (HA) patients is the development of alloantibodies (inhibitors) against factor VIII, which neutralizes the substituted factor. The primary genetic risk factors influencing the development of inhibitors are F8 gene mutations. Interleukins and cytokines that are involved in the regulation of B-lymphocyte development are other possible targets as genetic risk factors. This study assesses the possible involvement of 9 selected single nucleotide gene polymorphisms (SNPs) with interleukins (IL-4, IL-5, and IL-10), transforming growth factor beta 1 (TGF-β1), and interferon gamma (IFN-γ) in inhibitor development in severely affected HA patients carrying a null mutation in the F8 gene.
MATERIALS AND METHODS: A total of 173 HA patients were screened for intron 22 inversion and null mutations (nonsense and deletions). Genotyping of a total of 9 SNPs in genes IL-4, IL-5, IL-10, TGF-β1, and IFN-γ in 103 patients and 100 healthy individuals was carried out.
RESULTS: An association analysis between 42 inhibitor (+) and 61 inhibitor (-) patients showed a significant association with the T allele of rs2069812 in the IL-5 gene promoter and patients with inhibitors (p=0.0251). The TT genotype was also significantly associated with this group with a p-value of 0.0082, odds ratio of about 7, and confidence interval of over 90%, suggesting that it is the recessive susceptibility allele and that the C allele is the dominant protective allele.
CONCLUSION: The lack of other variants in the IL-5 gene of patients and controls suggests that rs2069812 may be a regulatory SNP and may have a role in B-lymphocyte development, constituting a genetic risk factor in antibody development.

Entities:  

Keywords:  Association study; F8 gene mutation; Hemophilia A; Inhibitor formation; Interleukins/cytokines; Single nucleotide gene polymorphisms

Year:  2014        PMID: 24764725      PMCID: PMC3996645          DOI: 10.4274/Tjh.2012.0197

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  18 in total

1.  Sample size requirements for matched case-control studies of gene-environment interaction.

Authors:  W James Gauderman
Journal:  Stat Med       Date:  2002-01-15       Impact factor: 2.373

Review 2.  Mutation profiling in haemophilia A.

Authors:  J Oldenburg
Journal:  Thromb Haemost       Date:  2001-04       Impact factor: 5.249

Review 3.  Inhibitors in congenital coagulation disorders.

Authors:  Nigel S Key
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

4.  Genotyping the hemophilia inversion hotspot by use of inverse PCR.

Authors:  Liliana Carmen Rossetti; Claudia Pamela Radic; Irene Beatriz Larripa; Carlos Daniel De Brasi
Journal:  Clin Chem       Date:  2005-04-28       Impact factor: 8.327

5.  Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

Authors:  Jan Astermark; Johannes Oldenburg; Joyce Carlson; Anna Pavlova; Kaan Kavakli; Erik Berntorp; Ann-Kari Lefvert
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

6.  Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

Authors:  Jan Astermark; Johannes Oldenburg; Anna Pavlova; Erik Berntorp; Ann-Kari Lefvert
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

Review 7.  Inhibitor development in correlation to factor VIII genotypes.

Authors:  J Oldenburg; O El-Maarri; R Schwaab
Journal:  Haemophilia       Date:  2002-03       Impact factor: 4.287

Review 8.  Interleukin 5 and B cell differentiation.

Authors:  K Takatsu
Journal:  Cytokine Growth Factor Rev       Date:  1998-03       Impact factor: 7.638

Review 9.  Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.

Authors:  A Coppola; C Santoro; A Tagliaferri; M Franchini; G DI Minno
Journal:  Haemophilia       Date:  2010-01       Impact factor: 4.287

10.  The Pennsylvania hemophilia program 1973-1978.

Authors:  M E Eyster; J H Lewis; S S Shapiro; F Gill; M Kajani; D Prager; I Djerassi; S Rice; C Lusch; A Keller
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

View more
  3 in total

1.  Association of Interleukin-10 gene promoter polymorphisms with obstructive sleep apnea.

Authors:  Sibel Özdaş; Talih Özdaş; Mustafa Acar; Selim S Erbek; Sabri Köseoğlu; Gökhan Göktürk; Afife Izbirak
Journal:  Sleep Breath       Date:  2015-07-03       Impact factor: 2.816

Review 2.  FVIII inhibitors: pathogenesis and avoidance.

Authors:  Jan Astermark
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

3.  Development of Acquired Hemophilia A After Treatment of Bronchial Asthma with Benralizumab.

Authors:  Hiroaki Kitamura; Yasushi Kubota; Rika Tomimasu; Haruki Hirakawa; Hiroshi Inoue; Hitomi Umeguchi; Moeko Yoshida; Hideki Akahoshi; Shiho Tsuruda; Rie Ide; Shinya Kimura; Masaharu Miyahara
Journal:  Indian J Hematol Blood Transfus       Date:  2020-10-21       Impact factor: 0.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.